伊奥尼斯制药 IONS 深 沪
等待开盘 03-26 09:30:00 美东时间
72.70
+3.020
+4.33%
华盛通- 最 高73.61
- 今 开70.68
- 成交量 299.43万股
- 最 低 70.68
- 昨 收 69.68
- 总市值 120.09亿
- 52周最高 86.74
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 23.95
- 委 比 -13.36%
- 总股本 1.65亿
- 历史最高 86.74
- 量 比 1.31
- 振 幅 4.20%
- 历史最低 6.25
- 每 手 1
- 风险率 20.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop
U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop March 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Equitable Holdings, Robinhood Markets and Wingstop on Thursday. HIGHLIGHTS * Equitable Holdi
今天 15:38
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
今天 11:41
The FDA Accepts For Priority Review Ionis Pharmaceuticals' New Drug Application For Zilganersen For Alexander disease, With PDUFA Date Of September 22, 2026
The NDA and Priority Review designation were based on results from the pivotal study of zilganersen in children and adults living with AxD. In the study, zilganersen 50 mg demonstrated statistically significant and
03-23 19:09
FDA accepts Ionis zilganersen NDA for Priority Review in Alexander disease
FDA accepts Ionis zilganersen NDA for Priority Review in Alexander disease The FDA accepted Ionis’ New Drug Application for zilganersen for Alexander disease and granted Priority Review. The PDUFA target action date is September 22, 2026. Disclaimer: This news brief was created by Public Technologie
03-23 19:02
美股盘后 | Healthpeak Properties, Inc.涨3.77%，QXO, Inc.涨3.06%
Healthpeak Properties, Inc.涨3.77%；QXO, Inc.涨3.06%；伊奥尼斯制药涨2.70%
03-21 06:10
GSK(GSK.US)乙肝新药在中国拟纳入优先审评 有望实现乙肝功能性治愈
3月17日，中国国家药监局药品审评中心(CDE)官网公示显示，葛兰素史克(GSK.US)申报的贝普若韦生注射液(Bepirovirsen solution for injection)拟纳入优先审评。
03-17 21:33
Ionis names Peter Reikes to board as Lynne Parshall and Joseph Wender retire in 2026
Ionis names Peter Reikes to board as Lynne Parshall and Joseph Wender retire in 2026 Ionis said board members Lynne Parshall and Joseph Wender will retire at the end of their terms, effective June 4, 2026. Peter Reikes will rejoin the board as a director on the same date. Reikes most recently served
03-09 19:00
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu
Cathie Wood’s ARK Invest ETFs reallocated majorly to AI and defense names, sharply increasing exposure to high-growth AI software and autonomous technology while cutting enterprise software, semicondu...
03-02 20:18
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
